PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH Announces P resentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI Interim results from the Phase 1 rESPECT trial of eryaspase plus mFOLFIRINOX as first-line treatment for advanced pancreatic cancer patients , presented in a poster presentation, confirm
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021
                Monthly information related to total number of voting rights and shares composing the share capital – December 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences Cambridge, MA (U.S.) and Lyon (France), January 3 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH Announces $7.85 Million Registered Direct Offering
ERYTECH Announces $ 7.85 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), December 14 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP) (the “Company”) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI
ERYTECH Announces P resentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI Full results of the Expanded Access Program in ‘ Double Allergic ’ a cute l ymphoblastic l eukemia ( AL L ) patients were presented this weekend at ASH
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2021
                Monthly information related to total number of voting rights and shares composing the share capital – November 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatment New patent granting adding to portfolio of 310 granted patents in 16 patent
View HTML
Toggle Summary ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET          Progress towards  seeking   approval  of  eryaspase  for the   treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase ; Fast   Track designation granted; submission of BLA
View HTML
Toggle Summary ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France) , November 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10)
View HTML
Top